5,719 results match your criteria Retinal Vein Occlusion


The Impact of Intravitreal Dexamethasone Implant (Ozurdex®) on Retrobulbar Hemodynamics in Patients with Diabetic Macular Edema and Retinal Vein Occlusions.

Cutan Ocul Toxicol 2019 Feb 17:1-23. Epub 2019 Feb 17.

a Department of Ophthalmology , Ministry of Health - Ordu University Research and Training Hospital , Ordu , 52200 / Turkey.

Objective: To evaluate the effect of single intravitreal Dexamethasone implant (Ozurdex®) on ocular blood flow velocities in patients with diabetic macular edema (DME) and retinal vein occlusions (RVO).

Methods: This prospective non-randomized interventional study included injected and fellow eyes of 12 patients with diabetic macular edema (DME) and of 16 patients with retinal vein occlusion (RVO) treated with intravitreal Ozurdex®. Color Doppler Ultrasonography (CDU) measures of the central retinal artery (CRA), posterior ciliary artery (PCA), ophthalmic artery (OA) those are peak systolic velocity (PSV), end diastolic velocity (EDV), resistive index (RI) and pulsatility index (PI) were performed in both injected and uninjected eyes before injection, at one week, one month after injection, and prior to re-injection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15569527.2019.1582061DOI Listing
February 2019

Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases.

Tohoku J Exp Med 2019 ;247(2):87-98

Department of Ophthalmology, The Second Xiangya Hospital, Central South University.

Ocular neovascular diseases are featured by abnormal angiogenesis in the eye, and they seriously threaten the human visual health. These diseases include proliferative diabetic retinopathy (PDR), age-related macular degeneration (AMD), retinopathy of prematurity (ROP), and retinal vein occlusion (RVO). In fact, ocular neovascular diseases represent the leading causes of vision impairment and blindness worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1620/tjem.247.87DOI Listing
January 2019

ACUTE MACULAR AND PERIPAPILLARY ANGIOGRAPHIC CHANGES WITH INTRAVITREAL INJECTIONS.

Retina 2019 Feb 11. Epub 2019 Feb 11.

Department of Ophthalmology, The New York Eye and Ear Infirmary of Mount Sinai, New York, New York.

Purpose: Intravitreal injections acutely and temporarily increase intraocular pressure (IOP), and this may have cumulative long-term effects including an increased risk for glaucoma surgery. This study was designed to measure retinal perfusion density changes on optical coherence tomography (OCT) angiography and OCT thickness alterations associated with acutely increased IOP after intravitreal injections.

Methods: Retrospective observational clinical study of 40 eyes (39 patients) with various retinopathies from October 2016 to June 2017 at a tertiary care retina clinic in NYC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IAE.0000000000002433DOI Listing
February 2019
1 Read

Branch retinal vein occlusion associated with platelet activation

Turk J Med Sci 2019 Feb 11;49(1):283-287. Epub 2019 Feb 11.

Background/aim: The aim of this study is to study subclinical platelet activation by detecting three important platelet activation parameters of mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) in patients with branch retinal vein occlusion (BRVO) in comparison to those in healthy control subjects.

Materials And Methods: This prospective study included 43 patients with BRVO (Group 1)and 40 control subjects (Group 2). The levels of MPV, PDW, and PCT were measured in both of the studied groups

Results: The mean serum level of MPV value was 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3906/sag-1807-223DOI Listing
February 2019

Papillophlebitis as manifestation of polyarteritis nodosa.

Arch Soc Esp Oftalmol 2019 Feb 4. Epub 2019 Feb 4.

Servicio de Cardiología, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas de Gran Canaria, Las Palmas, España.

A 35 year-old-man diagnosed with polyarteritis nodosa developed papillophlebitis on his left eye. Throughout the evolution of the disease, he had a macular oedema treated with intravitreal injections of aflibercept, with adequate recovery of visual acuity. He also had episcleritis on the other eye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oftal.2018.12.007DOI Listing
February 2019

Early-scatter laser photocoagulation promotes the formation of collateral vessels in branch retinal vein occlusion.

Eur J Ophthalmol 2019 Feb 5:1120672119827857. Epub 2019 Feb 5.

Department of Ophthalmology, Dong-A University Hospital, Busan, Republic of Korea.

Purpose:: To investigate the effect of early-scatter laser photocoagulation on the formation of collateral vessels in branch retinal vein occlusion.

Methods:: The medical records of 40 cases (40 patients) of branch retinal vein occlusion with macular edema were retrospectively reviewed. Of them, 23 patients were treated with intravitreal bevacizumab injection and 17 patients underwent intravitreal bevacizumab injection with additional laser treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1120672119827857DOI Listing
February 2019

Microvascular Retinal and Choroidal Changes in Retinal Vein Occlusion Analyzed by Two Different Optical Coherence Tomography Angiography Devices.

Ophthalmologica 2019 Feb 5:1-8. Epub 2019 Feb 5.

Department of Ophthalmology, University Vita-Salute, IRCCS Ospedale San Raffaele, Milan,

Purpose: To investigate retinal and choroidal microvascular changes and structural choroidal involvement in retinal vein occlusion (RVO).

Methods: Retrospective analysis of treatment-naïve macular edema secondary to RVO, studied by optical coherence tomography (OCT) and OCT angiography (OCTA), before and after the loading phase of intravitreal injections of ranibizumab (IVR-LP). OCTA was performed using two different devices: AngioVue RTVue XR Avanti (spectral-domain OCTA) and Zeiss PLEX® Elite 9000 (swept-source OCTA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496195DOI Listing
February 2019

Macular Branch Retinal Vein Occlusion as a Rare Complication of Periocular Scorpion Bite: A Case Report and Literature Review.

Bull Emerg Trauma 2019 Jan;7(1):76-79

Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.29252/beat-0701012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360004PMC
January 2019

Optical coherence tomography angiography findings in Behcet patients.

Int Ophthalmol 2019 Feb 1. Epub 2019 Feb 1.

Department of Ophthalmology, Ege University School of Medicine, İzmir, Turkey.

Purpose: Retinal vasculitis and vein occlusions are common causes of serious visual loss in Behçet's disease. We aimed to evaluate the optical coherence tomography angiography (OCTA) findings of Behcet uveitis (BU) patients.

Methods: We evaluated 32 eyes of 16 patients with BU and 30 eyes of 15 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10792-019-01080-1DOI Listing
February 2019
1 Read

Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion.

Surv Ophthalmol 2019 Jan 28. Epub 2019 Jan 28.

Department of Ophthalmology, University of Medicine Cluj-Napoca/Romania. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.survophthal.2019.01.006DOI Listing
January 2019

Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach.

Acta Ophthalmol 2019 Jan 31. Epub 2019 Jan 31.

Retina Consultants of Houston, Houston, Texas, USA.

Delivery of pharmaceuticals to the posterior segment presents challenges that arise from the anatomy and clearance pharmacokinetics of the eye. Systemic and several local administration options [topical, periocular, intravitreal (IVT) and subretinal] are in clinical use, each with a unique benefit to risk profile shaped by factors including the administered agent, frequency of dosing, achievable pharmaceutical concentrations within posterior segment structures versus elsewhere in the eye or the body, invasiveness of the procedure and the inherent challenges with some administration methods. The use of the suprachoroidal space (SCS), which is the region between the sclera and the choroid, is being explored as a potential approach to target pharmacotherapies to the posterior segment via a minimally invasive injection procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/aos.14042DOI Listing
January 2019
1 Read

The Nd:YAG laser as first-line treatment for fibrin pupillary-block glaucoma following uncomplicated cataract surgery.

Oxf Med Case Reports 2019 Jan 24;2019(1):omy113. Epub 2019 Jan 24.

Ophthalmology Department, Great Western Hospital, Swindon, UK.

A 43-year-old lady presented with painful, loss of vision in the right eye 2 weeks after cataract surgery. This is on a background of previous central retinal vein occlusion in the right eye and bilateral diabetic retinopathy. Her past medical history included mixed connective tissue disease for which she is on systemic immunosuppressants. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/omcr/article/doi/10.1093/omcr/omy11
Publisher Site
http://dx.doi.org/10.1093/omcr/omy113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345086PMC
January 2019
4 Reads

Understanding quality of life impact in people with retinal vein occlusion: a qualitative inquiry.

Clin Exp Optom 2019 Jan 29. Epub 2019 Jan 29.

Optometry and Vision Science, Flinders University, Adelaide, South Australia, Australia.

Background: Although being the second most common sight-threatening retinal vascular disease after diabetic retinopathy, the patient-centred impact of retinal vein occlusion has not been well studied. This study aims to understand the quality of life issues in people with retinal vein occlusion using a qualitative methodology.

Methods: In-depth semi-structured interviews were conducted with 17 patients with retinal vein occlusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cxo.12875DOI Listing
January 2019

Incidence of Open-angle Glaucoma in Newly Diagnosed Retinal Vein Occlusion: A Nationwide Population-based Study.

J Glaucoma 2019 Feb;28(2):111-118

Department of Ophthalmology, Seoul National University Hospital, Seoul National University College of Medicine.

Purpose: The purpose of this study was to compare the incidence of open-angle glaucoma (OAG) in patients with newly diagnosed retinal vein occlusion (RVO) with that in the general population in order to determine the association between OAG and RVO.

Methods: The Korean Health Insurance Review and Assessment (HIRA) data from 2011 through 2015 was analyzed in order to determine the incidence rates of OAG in the general population and in patients with newly diagnosed RVO based on the diagnostic code. The standardized incidence ratios (SIRs) of OAG in patients with RVO were determined with respect to the age- and sex-matched general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IJG.0000000000001134DOI Listing
February 2019

Quantity and quality of image artifacts in optical coherence tomography angiography.

PLoS One 2019 25;14(1):e0210505. Epub 2019 Jan 25.

Department of Ophthalmology, Ulm University, Ulm, Germany.

Objective: To analyze quality and frequency of OCTA artifacts and to evaluate their impact on the interpretability of OCTA images.

Design: 75 patients with diabetic retinopathy (DR), retinal artery occlusion (RAO), retinal vein occlusion (RVO), or neovascular age-related macular degeneration (nAMD) and healthy controls were enrolled in this cross-sectional study in the outpatient department of a tertiary eye care center.

Methods: All participants underwent an OCTA examination (spectral domain OCT Cirrus 5000 equipped with the AngioPlex module). Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210505PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347178PMC
January 2019
9 Reads

OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.

Retina 2019 Jan 23. Epub 2019 Jan 23.

Department of Ophthalmology, Miguel Servet University Hospital, IIS-Aragon, Zaragoza, Spain.

Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. This review aims to provide an update of the ocular adverse events (OAEs), especially retinal toxicity, associated with the use of MEK inhibitors.

Methods: We conducted a scientific literature search using the PubMed database up to July 2018 with the terms "MEK inhibitors" with a "review" filter and "MEK inhibitors" with a "clinical trials" filter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IAE.0000000000002451DOI Listing
January 2019
5 Reads

Short-term effect of intravitreal conbercept injection on major and macular branch retinal vein occlusion.

J Int Med Res 2019 Jan 25:300060518819613. Epub 2019 Jan 25.

2 Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, P.R. China.

Objective: To evaluate the effectiveness of intravitreal conbercept injection on major and macular branch retinal vein occlusion (BRVO).

Methods: This retrospective analysis involved 43 patients with BRVO (major BRVO n = 24; macular BRVO, n = 19) who were diagnosed by fluorescein fundus angiography (FFA) and injected with intravitreal conbercept. The following outcomes were measured at baseline and follow-up (1-6 months): best-corrected visual acuity (BCVA), central foveal thickness (CFT), total retinal volume in a 6-mm diameter section of the macula, choroidal thickness under the central fovea of the macula, relative area of retinal hemorrhage, complications, and times when repeated injection was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060518819613DOI Listing
January 2019
1 Read

CORRELATION OF EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AVERAGING VERSUS SINGLE-IMAGE QUANTITATIVE MEASUREMENTS WITH RETINAL VEIN OCCLUSION VISUAL OUTCOMES.

Retina 2019 Jan 22. Epub 2019 Jan 22.

Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons, New York, New York.

Purpose: To demonstrate the effect of averaging multiple en face optical coherence tomography angiography images on the correlation between retinal microvasculature quantitative metrics and best-corrected visual acuity (BCVA) in eyes with retinal vein occlusion.

Methods: A cross-sectional cohort with unilateral retinal vein occlusion was imaged in both eyes. Five 3 mm × 3-mm spectral domain optical coherence tomography angiography images were averaged, and quantitative parameters from averaged versus single images were correlated with logMAR BCVA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IAE.0000000000002453DOI Listing
January 2019
4 Reads

Successful Total Resection of an Orbital Epithelioid Hemangioendothelioma with the Aid of Endovascular Embolization.

Ocul Oncol Pathol 2019 Jan 30;5(1):50-53. Epub 2018 May 30.

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Hemangioendothelioma is rarely encountered in the orbit. We present a patient with a growing orbital mass for whom surgical excision was planned. Two previous attempts at removing the mass failed due to profuse bleeding. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/489126
Publisher Site
http://dx.doi.org/10.1159/000489126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341328PMC
January 2019
3 Reads

Comment on: Bilateral combined central retinal artery and vein occlusion in a 3-year-old child with nephrotic syndrome.

Indian J Ophthalmol 2019 Feb;67(2):312-313

Department of Ophthalmolgy, S.S. Medical College, Rewa, Madhya Pradesh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijo.IJO_1633_18DOI Listing
February 2019
1 Read

A complication of ischemic branch retinal vein occlusion.

Indian J Ophthalmol 2019 Feb;67(2):276

Vitreo-Retinal Services, Giridhar Eye Institute, Ponneth Temple Road, Kadavanthra, Kochi, Kerala, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijo.IJO_882_18DOI Listing
February 2019
3 Reads

A rare case having hemi-retinal artery occlusion in one eye and hemi-retinal vein occlusion in the other: Diverse manifestations of retinal vascular occlusion.

Indian J Ophthalmol 2019 Feb;67(2):273-274

Dr RP Centre for Ophthalmic Sciences, AIIMS, New Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijo.IJO_987_18DOI Listing
February 2019
6 Reads

Dexamethasone implant for immunogammopathy maculopathy associated with IgA multiple myeloma.

Ther Adv Ophthalmol 2019 Jan-Dec;11:2515841418820441. Epub 2019 Jan 8.

Department of Ophthalmology, Medical School, University of Patras, Patras, Greece.

Background: We describe a case where hyperviscosity retinopathy and immunogammopathy maculopathy were the presenting features of IgA multiple myeloma and report the response of maculopathy to intravitreal injection of dexamethasone implants.

Case Presentation: A 56-year-old man presented at the Department of Ophthalmology with the chief complain of reduced vision for the past 10 days in both eyes. Ophthalmic examination revealed central retinal vein occlusion resembling signs with severe macular edema in both eyes with prominent serous macular detachment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2515841418820441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329023PMC
January 2019
1 Read

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials.

Drug Des Devel Ther 2019 11;13:301-307. Epub 2019 Jan 11.

Department of Ophthalmology, Ninghai First Hospital, Zhejiang 315600, People's Republic of China,

Purpose: The purpose of this meta-analysis was to compare the efficacy and safety of corticosteroid implant and intravitreal ranibizumab for the treatment of macular edema (ME).

Materials And Methods: PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials were comprehensively searched for studies comparing dexamethasone implant with ranibizumab in patients with ME. Best-corrected visual acuity (BCVA), central subfield thickness (CST), and adverse events were extracted from the final eligible studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S184520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333386PMC
January 2019
1 Read
3.028 Impact Factor

Bilateral simultaneous central retinal vein occlusion revealing Waldenström's macroglobulinemia.

Presse Med 2019 Jan 18. Epub 2019 Jan 18.

University of Sfax, Habib Bourguiba University Hospital, Faculty of Medicine, Department of Ophthalmology, Sfax, Tunisia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2018.11.004DOI Listing
January 2019

AQUEOUS HUMOR CYTOKINES AND THERAPEUTIC CUSTOMIZATION IN NONRESPONDING MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.

Retin Cases Brief Rep 2019 Jan 17. Epub 2019 Jan 17.

Vitreoretina Services, Narayana Nethralaya, Bengaluru, India.

Aim: To report an alternative cytokine-based customized therapeutic approach of macular edema secondary to retinal vein occlusion.

Methods: A 64-year-old male patient presented with left eye macular edema secondary to central retinal vein occlusion, status after three consecutive anti-vascular endothelial growth factor injections. He was subsequently subjected to aqueous humor cytokine analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICB.0000000000000768DOI Listing
January 2019
1 Read

Deep-learning classifier with ultrawide-field fundus ophthalmoscopy for detecting branch retinal vein occlusion.

Int J Ophthalmol 2019 18;12(1):94-99. Epub 2019 Jan 18.

Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 7708503, Japan.

Aim: To investigate and compare the efficacy of two machine-learning technologies with deep-learning (DL) and support vector machine (SVM) for the detection of branch retinal vein occlusion (BRVO) using ultrawide-field fundus images.

Methods: This study included 237 images from 236 patients with BRVO with a mean±standard deviation of age 66.3±10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18240/ijo.2019.01.15DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326931PMC
January 2019

Development of a Novel Model of Central Retinal Vascular Occlusion and the Therapeutic Potential of the Adrenomedullin-Receptor Activity-Modifying Protein 2 System.

Am J Pathol 2019 Feb 15;189(2):449-466. Epub 2019 Jan 15.

Department of Cardiovascular Research, Shinshu University Graduate School of Medicine, Nagano, Japan. Electronic address:

Central retinal vein occlusion (CRVO) is an intractable disease that causes visual acuity loss with retinal ischemia, hemorrhage, and edema. In this study, we developed an experimental CRVO model in mice and evaluated the therapeutic potential of the pleiotropic peptide adrenomedullin (ADM) and its receptor activity-modifying protein 2 (RAMP2). The CRVO model, which had phenotypes resembling those seen in the clinic, was produced by combining i. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00029440183057
Publisher Site
http://dx.doi.org/10.1016/j.ajpath.2018.10.021DOI Listing
February 2019
4 Reads

Efficacy of panretinal laser in ischemic central retinal vein occlusion: A systematic review.

Exp Ther Med 2019 Jan 29;17(1):901-910. Epub 2018 Nov 29.

Department of Ophthalmology, Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong 266000, P.R. China.

The aim of the present systematic review was to assess the efficacy of laser therapy for ischemic central retinal vein occlusion (CRVO). Relevant studies were retrieved by searching the PubMed, Embase, Chinese Biomedical Literature Database and, Chinese Science and Technology Periodicals databases using a combination of key words, including 'central retinal vein obstruction', 'CRVO', 'laser' and 'panretinal photocoagulation'. The titles, abstracts and full texts were screened by two independent reviewers and studies were selected according to specific inclusion criteria. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/etm.2018.7034
Publisher Site
http://dx.doi.org/10.3892/etm.2018.7034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307409PMC
January 2019
4 Reads

Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab.

BMC Ophthalmol 2019 Jan 16;19(1):19. Epub 2019 Jan 16.

Department of Ophthalmology, Toho University Ohashi Medical Center, 2-22-36, Ohashi, Meguro-ku, Tokyo, 153-8515, Japan.

Background: To report the first case of human herpesvirus-6 (HHV-6) corneal endotheliitis that developed after intravitreal ranibizumab injections.

Case Presentation: A 63-year-old man with a medical history of diabetes and systemic steroid treatment for bullous pemphigoid had been receiving intravitreal injections of ranibizumab in the left eye for 2 years according to a Pro Re Nata treatment regimen for macular edema associated with branch retinal vein occlusion. Twenty days after the last injection, the patient presented with pain and decreased visual acuity in his left eye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12886-019-1032-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335734PMC
January 2019
2 Reads

Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®).

Ther Adv Ophthalmol 2019 Jan-Dec;11:2515841418820755. Epub 2019 Jan 5.

Centro Hospitalar do Porto, Porto, Portugal.

Introduction: Macular edema after central retinal vein occlusion is a common cause of vision loss. Upregulation of vascular endothelial growth factor and higher levels of inflammatory mediators have been involved in the pathogeny of the macular edema in central retinal vein occlusion.

Case Report: The authors report a case with non-ischemic central retinal vein occlusion that was successfully treated with a single sustained-release fluocinolone acetonide intravitreal implant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2515841418820755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322089PMC
January 2019

Functional and morphologic study of retinal hypoperfusion injury induced by bilateral common carotid artery occlusion in rats.

Sci Rep 2019 Jan 14;9(1):80. Epub 2019 Jan 14.

Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, 100029, China.

Retinal hypoperfusion injury is the pathophysiologic basis of ocular ischemic syndrome (OIS) which often leads to severe visual loss. In this study, we aimed to establish a rat model of retinal chronic hypoperfusion by bilateral common carotid artery occlusion (BCCAO) and observe changes in the retinal function and morphology. We found that model rats showed retinal arteriosclerosis, slight dilated retinal vein, small hemangiomas, hemorrhages, vascular segmental filling, and nonperfused areas after 2 weeks of BCCAO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-36400-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331588PMC
January 2019
1 Read

OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.

Retina 2019 Jan 10. Epub 2019 Jan 10.

Department of Ophthalmology, First Affiliated Hospital of Dalian Medical University, Dalian, China.

Purpose: To identify the spectral domain optical coherence tomography predictors of visual prognosis in retinal vein occlusion macular edema after intravitreal conbercept injection.

Methods: Retrospective cohort study of 63 treatment-naive retinal vein occlusion macular edema eyes received pro re nata intravitreal conbercept with at least 3 months of follow-up. The best-corrected visual acuity (BCVA) and optical coherence tomography scans were recorded at baseline, 1 month, and 3 months after starting therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IAE.0000000000002444DOI Listing
January 2019

Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion.

BMC Ophthalmol 2019 Jan 8;19(1):11. Epub 2019 Jan 8.

Genentech, Inc., South San Francisco, CA, USA.

Background: To identify baseline patient characteristics associated with early clinically significant visual acuity (VA) improvements within 3 months of treatment initiation in ranibizumab-treated patients with retinal vein occlusion (RVO) in the SHORE study.

Methods: Post hoc analysis of baseline patient characteristics in the randomized, open-label, vision examiner-masked SHORE phase 4 study that compared monthly versus pro re nata dosing of ranibizumab in patients with branch and central RVO. Patients who enrolled in SHORE fulfilled eligibility criteria per protocol (N = 202). Read More

View Article

Download full-text PDF

Source
https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12
Publisher Site
http://dx.doi.org/10.1186/s12886-018-1012-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325686PMC
January 2019
7 Reads

Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis.

BMC Ophthalmol 2019 Jan 8;19(1). Epub 2019 Jan 8.

Ophthalmology Department, General Navy Hospital of Chinese People's Liberation Army, Beijing, 100048, China.

Background: Retinal vein occlusion (RVO) is a common retinal venous disorder that causes vision loss. No specific therapy has been developed. Controversy exists regarding two treatments: intravitreal dexamethasone implants and anti-vascular endothelial growth factor (VEGF). Read More

View Article

Download full-text PDF

Source
https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12
Publisher Site
http://dx.doi.org/10.1186/s12886-018-1016-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325672PMC
January 2019
6 Reads

Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.

Graefes Arch Clin Exp Ophthalmol 2019 Jan 4. Epub 2019 Jan 4.

Department of Ophthalmology, University Medical Center Goettingen, Robert-Koch-Str 40, 37075, Goettingen, Germany.

Background: The objective of the study was the investigation of the effects of intravitreal bevacizumab (BEV) with or without additional macular grid laser photocoagulation (GRID) for macular edema (ME) secondary to branch retinal vein occlusion (BRVO).

Methods: Prospective, randomized, monocentric study. Thirty-two patients were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00417-018-04223-9DOI Listing
January 2019

Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world.

PLoS One 2019 4;14(1):e0209997. Epub 2019 Jan 4.

Institut Clínic d´Oftalmología (ICOF), Hospital Clinic, Barcelona, Spain.

Purpose: To evaluate the long-term cumulative probability of intraocular pressure (IOP) elevation with the intravitreal dexamethasone implant (IDI) when used to treat different indications: diabetic macular edema, uveitis, retinal vein occlusion.

Methods: 705 IDI injections (429 eyes) were assessed and Kaplan-Meier graphs were generated to assess: the probability of different levels of IOP elevation (IOP≥21, ≥25 or ≥35 mmHg), IOP change ≥10 mmHg, initiation of IOP-lowering treatment, glaucoma surgery, IOP change with repeat injections and IOP elevation in eyes with glaucoma and ocular hypertension (OHT).

Results: The cumulative probability of IOP ≥21, ≥25 and ≥35 mmHg was 50%-60%, 25%-30% and 6%-7% at 12-24 months, respectively. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209997PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319768PMC
January 2019
2 Reads

Quantitative measurement of vascular density and flow using optical coherence tomography angiography (OCTA) in patients with central retinal vein occlusion: Can OCTA help in distinguishing ischemic from non-ischemic type?

Int J Retina Vitreous 2018 27;4:47. Epub 2018 Dec 27.

Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Science, Qazvin Square, 1336616351 Tehran, Iran.

Background: To evaluate microvascular changes and quantitative parameters in patients with central retinal vein occlusion (CRVO) by using optical coherence tomography angiography (OCTA) and finding difference between presumably ischemic and non ischemic CRVO.

Methods: Patients with CRVO (31) and healthy control (20) were enrolled in this observational case control study. The OCTA was done for each patient and control subject. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40942-018-0152-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307124PMC
December 2018

Rapid progression of cataract to mature stage after intravitreal dexamethasone implant injection: a case report.

BMC Ophthalmol 2019 Jan 3;19(1). Epub 2019 Jan 3.

Department of Ophthalmology, Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-ro, Nowon-Gu, Seoul, 139-707, South Korea.

Background: This study aims to report a case of rapid progression of cataract to mature stage after intravitreal dexamethasone implantation for macular edema due to branch retinal vein occlusion.

Case Presentation: A 59-year-old Korean male with complaints of sudden metamorphopsia and reduced visual acuity for three days in the left eye was referred to our clinic. Ophthalmological investigations included fundus photography, fluorescein angiography, and optical coherence tomography. Read More

View Article

Download full-text PDF

Source
https://bmcophthalmol.biomedcentral.com/articles/10.1186/s12
Publisher Site
http://dx.doi.org/10.1186/s12886-018-1008-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318997PMC
January 2019
14 Reads

[Subconjunctival Ozurdex injection in branch retinal vein occlusion].

J Fr Ophtalmol 2019 Jan 26;42(1):89-91. Epub 2018 Dec 26.

Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille, France; Service d'ophtalmologie, hôpital Nord, AP-HM, chemin des Bourrely, 13915 Marseille cedex 20, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2018.03.030DOI Listing
January 2019

Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.

BMJ Open 2018 Dec 28;8(12):e022700. Epub 2018 Dec 28.

Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.

Objectives: To evaluate the efficacy and safety of anti-vascular endothelial growth factor (VEGF) agents and corticosteroids for the treatment of macular oedema (ME) secondary to central retinal vein occlusion (CRVO).

Design: Systematic review and network meta-analysis.

Participants: Patients from previously reported randomised controlled trials (RCTs) comparing anti-VEGF and corticosteroids for the treatment of ME secondary to CRVO. Read More

View Article

Download full-text PDF

Source
http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-02270
Publisher Site
http://dx.doi.org/10.1136/bmjopen-2018-022700DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318534PMC
December 2018
1 Read

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.

JAMA Ophthalmol 2018 Dec 27. Epub 2018 Dec 27.

Paducah Retinal Center, Paducah, Kentucky.

Importance: Information is needed to assess switching treatment in eyes with a poor response to 6 months of monthly administration of aflibercept or bevacizumab for macular edema from central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).

Objective: To investigate visual acuity letter score (VALS) and central subfield thickness (CST) changes from month 6 to 12 among eyes with a poor response at month 6 to monthly dosing of aflibercept or bevacizumab in the Study of Comparative Treatments for Retinal Vein Occlusion 2.

Design, Setting, And Participants: This secondary analysis of the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) was conducted at 66 private practice or academic centers in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaophthalmol.2018.6111DOI Listing
December 2018

Treatment controversies in a rare case of a simultaneous branch retinal artery and vein occlusion secondary to hyperhomocysteinemia and hypertension.

Int J Ophthalmol 2018 18;11(12):2024-2026. Epub 2018 Dec 18.

General Hospital of Patras "Agios Andreas", Ophthalmology Clinic, Kalavriton 37, Patras 26335, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18240/ijo.2018.12.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288539PMC
December 2018

Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis.

Clin Ophthalmol 2018 6;12:2519-2534. Epub 2018 Dec 6.

Allergan Plc, Irvine, CA, USA.

Purpose: To evaluate the long-term safety of dexamethasone intravitreal implant (DEX) in patients treated for macular edema associated with retinal vein occlusion (RVO) or noninfectious posterior segment uveitis (NIPSU) in clinical practice.

Patients And Methods: Multicenter (102 sites in France, Germany, Spain, UK), prospective, observational, post-authorization safety study in adult patients treated with DEX. Data collected up to 2 years after enrollment included serious adverse events (SAEs) and adverse events of special interest (AESIs; adverse drug reactions that are considered important risks associated with DEX and listed in the European Union Ozurdex Risk Management Plan). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OPTH.S181256DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287662PMC
December 2018
5 Reads

Acute Onset of Exogenous Endophthalmitis after Dexamethasone Implant Injection Treated without Implant Removal.

Case Rep Ophthalmol Med 2018 18;2018:4614802. Epub 2018 Nov 18.

Ophthalmology Clinic, Medical Retina & Vitreoretinal Surgery Department, Venizeleio Hospital of Crete, Knossos Avenue 44, Heraklion of Crete, Greece.

We present a case of acute endophthalmitis after intravitreal dexamethasone implant injection and discuss the management of this rare and challenging case in which the implant could not be removed. A 50-year-old woman with a history of branch retinal vein occlusion in the right eye was treated with intravitreal dexamethasone implant injection for macular oedema. Four days after injection, the patient was admitted to the department with acute pain, decreased vision, and redness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4614802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276387PMC
November 2018

Unilateral central retinal vein occlusion as a first manifestation of diabetes mellitus in a ten-year-old girl.

Saudi J Ophthalmol 2018 Oct-Dec;32(4):346-348. Epub 2018 Feb 27.

Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.

Central retinal vein occlusion (CRVO) is relatively rare in the pediatric age group. We present a case of CRVO as the first manifestation of diabetes mellitus in a ten-year-old girl. The associated macular edema was managed successfully with a single injection of Ranibizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sjopt.2018.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300750PMC
February 2018

Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion.

Mol Vis 2018 26;24:759-766. Epub 2018 Nov 26.

Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark.

Purpose: To identify retinal protein changes that mediate beneficial effects of intravitreal bevacizumab in experimental branch retinal vein occlusion (BRVO).

Methods: In six Danish Landrace pigs, BRVO was induced with argon laser in both eyes. After BRVO was induced, the right eye of each animal was given an intravitreal injection of bevacizumab while the left eye was treated with saline water. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279196PMC
November 2018
6 Reads

[Foveal avascular zone and OCT angiography. An overview of current knowledge].

Ophthalmologe 2018 Dec 19. Epub 2018 Dec 19.

Klinik für Augenheilkunde, Universitätsklinikum Münster, Domagkstr. 15, 48149, Münster, Deutschland.

Background: The foveal avascular zone (FAZ) has often been analyzed under different aspects in the last decades, mainly by fluorescence angiography (FA); however, the novel technology of optical coherence tomography angiography (OCTA) enables a non-invasive examination, visualization and quantitative analysis of the FAZ, which has recently led to many new findings, especially in a multidisciplinary manner. This article provides an overview of the investigation of the FAZ using OCTA and the new findings that have been obtained using OCTA in recent years.

Methods: This article is based on a comprehensive literature review. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00347-018-0838-2
Publisher Site
http://dx.doi.org/10.1007/s00347-018-0838-2DOI Listing
December 2018
6 Reads

Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant.

BMJ Case Rep 2018 Dec 13;11(1). Epub 2018 Dec 13.

Royal Eye Infirmary, University hospitals of Plymouth NHS Trust, Plymouth, UK.

Ozurdex (Allergan, Irvine, California, USA) is a biodegradable sustained release intravitreal implant containing 0.7 mg dexamethasone in a solid polymer drug delivery system. In the UK, it is approved for use in patients with macular oedema secondary to retinal vein occlusion, diabetic maculopathy and non-infectious uveitis. Read More

View Article

Download full-text PDF

Source
http://casereports.bmj.com/lookup/doi/10.1136/bcr-2018-22705
Publisher Site
http://dx.doi.org/10.1136/bcr-2018-227055DOI Listing
December 2018
3 Reads